CHF158.15
0.19%
SIX Swiss Exchange, Sep 18, 05:31 pm CEST. Closed.
ISIN
CH1335392721
Symbol
GALD
Index

Galderma Target price 2026 - Analyst rating & recommendation

Galderma Classifications & Recommendation

Buy
87%
Hold
13%

Galderma Price Target

Target Price CHF204.00
Price CHF158.15
Potential
Number of Estimates 19
19 Analysts have issued a price target Galderma 2027 . The average Galderma target price is CHF204.00. This is higher than the current stock price. The highest price target is
CHF273.00 72.62%
register free of charge
, the lowest is .
A rating was issued by 23 analysts: 20 Analysts recommend Galderma to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Galderma stock has an average upside potential 2027 of . Most analysts recommend the Galderma stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion CHF 4.31 5.35
18.04% 24.27%
EBITDA Margin 17.63% 25.90%
19.13% 46.91%

20 Analysts have issued a sales forecast Galderma 2026 . The average Galderma sales estimate is

CHF5.4b
unlock
. This is
9.96% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF5.6b 14.98%
unlock
, the lowest is
CHF5.0b 3.31%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 CHF4.3b 18.04%
2026
CHF5.4b 24.27%
unlock
2027
CHF6.3b 17.15%
unlock
2028
CHF7.3b 15.61%
unlock
2029
CHF8.2b 13.24%
unlock
2030
CHF9.2b 11.44%
unlock
2031
CHF9.8b 7.46%
unlock
2032
CHF10.7b 8.59%
unlock
2033
CHF11.6b 9.03%
unlock

18 Analysts have issued an Galderma EBITDA forecast 2026. The average Galderma EBITDA estimate is

CHF1.4b
unlock
. This is
14.14% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF1.5b 19.62%
unlock
, the lowest is
CHF1.3b 3.65%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 CHF760m 4.55%
2026
CHF1.4b 82.58%
unlock
2027
CHF1.8b 28.22%
unlock
2028
CHF2.2b 25.43%
unlock
2029
CHF2.6b 18.28%
unlock
2030
CHF3.1b 15.92%
unlock
2031
CHF3.5b 13.55%
unlock
2032
CHF3.9b 13.52%
unlock
2033
CHF3.6b 8.53%
unlock

EBITDA Margin

2025 17.63% 19.13%
2026
25.90% 46.91%
unlock
2027
28.35% 9.46%
unlock
2028
30.76% 8.50%
unlock
2029
32.13% 4.45%
unlock
2030
33.42% 4.01%
unlock
2031
35.31% 5.66%
unlock
2032
36.91% 4.53%
unlock
2033
30.97% 16.09%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share CHF 2.13 4.01
166.25% 88.26%
P/E 39.42
EV/Sales 7.17

20 Analysts have issued a Galderma forecast for earnings per share. The average Galderma EPS is

CHF4.01
unlock
. This is
33.22% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
CHF4.28 42.19%
unlock
, the lowest is
CHF3.68 22.26%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 CHF2.13 166.25%
2026
CHF4.01 88.26%
unlock
2027
CHF5.47 36.41%
unlock
2028
CHF7.13 30.35%
unlock
2029
CHF8.49 19.07%
unlock
2030
CHF9.34 10.01%
unlock
2031
CHF9.45 1.18%
unlock
2032
CHF10.55 11.64%
unlock
2033
CHF15.29 44.93%
unlock

P/E ratio

Current 52.54 54.23%
2026
39.42 24.97%
unlock
2027
28.92 26.64%
unlock
2028
22.19 23.27%
unlock
2029
18.64 16.00%
unlock
2030
16.93 9.17%
unlock
2031
16.74 1.12%
unlock
2032
14.99 10.45%
unlock
2033
10.34 31.02%
unlock

Based on analysts' sales estimates for 2026, the Galderma stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.89
2026
7.17 9.08%
unlock
2027
6.12 14.64%
unlock
2028
5.30 13.50%
unlock
2029
4.68 11.69%
unlock
2030
4.20 10.27%
unlock
2031
3.91 6.95%
unlock
2032
3.60 7.91%
unlock
2033
3.30 8.28%
unlock

P/S ratio

Current 7.56 18.56%
2026
6.87 9.06%
unlock
2027
5.87 14.64%
unlock
2028
5.08 13.50%
unlock
2029
4.48 11.69%
unlock
2030
4.02 10.27%
unlock
2031
3.74 6.95%
unlock
2032
3.45 7.91%
unlock
2033
3.16 8.28%
unlock

Current Galderma Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JEFFERIES
Locked
Locked
Locked Jul 07 2026
H.C. WAINWRIGHT & CO., LLC
Locked
Locked
Locked Jul 01 2026
ODDO BHF
Locked
Locked
Locked Jun 30 2026
BERENBERG
Locked
Locked
Locked Jun 15 2026
BERENBERG
Locked
Locked
Locked Feb 20 2026
JEFFERIES
Locked
Locked
Locked Feb 16 2026
BERENBERG
Locked
Locked
Locked Jan 26 2026
Analyst Rating Date
Locked
JEFFERIES:
Locked
Locked
Jul 07 2026
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
Locked
Jul 01 2026
Locked
ODDO BHF:
Locked
Locked
Jun 30 2026
Locked
BERENBERG:
Locked
Locked
Jun 15 2026
Locked
BERENBERG:
Locked
Locked
Feb 20 2026
Locked
JEFFERIES:
Locked
Locked
Feb 16 2026
Locked
BERENBERG:
Locked
Locked
Jan 26 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today